| Autor: |
Al Tabaa Y; Scintidoc Nuclear Medicine Center, Clinique Clémentville, Montpellier France., Casasnovas RO; Hematology, Le Centre Hospitalier Universitaire (CHU) François Mitterrand, Dijon, France., Baillet C; Nuclear Medicine, CHU Lille, Lille, France., Bachy E; Hematology, CHU Lyon, Lyon, France., Nicolas-Virelizier E; Hematology, Centre de Recherche en Cancerologie de Lyon, Lyon, France., Schiano De Colella JM; Hematology, Institut Paoli-Calmettes, Marseille, France., Bailly C; Nuclear Medicine, CHU Nantes, Nantes, France., Kanoun S; Team 9, Centre de Recherche Clinique de Toulouse, Toulouse, France., Guidez S; Hematology, CHU Poitiers, Poitiers, France., Gyan E; Hematology and cell therapy Department, CIC INSERM U1415, CHU Tours, University of Tours, Tours, France., Gressin R; Hematology, CHU Grenoble, Grenoble, France., Morineau N; Hematology, CHD Vendée, La Roche sur Yon, France., Ysebaert L; Hematology, Oncopole Toulouse, Toulouse, France., Le Gouill S; Hematology, CHU Nantes, Nantes, France., Tilly H; Hematology, Centre Henri Becquerel, Rouen, France., Houot R; Hematology, CHU Rennes, Rennes, France., Morschhauser F; Hematology, CHU Lille, Lille, France., Cartron G; Hematology, CHU Montpellier, Montpellier, France., Herbaux C; Hematology, CHU Montpellier, Montpellier, France. |
